

MACROGENICS INC  
Form 8-K  
March 10, 2016  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 8, 2016

MACROGENICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware                                      001-36112      06-1591613  
(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation)                      File Number) Identification No.)

9640 Medical Center Drive,                                      20850  
Rockville, Maryland  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (301) 251-5172

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: MACROGENICS INC - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective March 8, 2016, MacroGenics, Inc. (the "Company") entered into an Employment Agreement with Ezio Bonvini, M.D. (the "Employment Agreement"). Dr. Bonvini is the Company's Senior Vice President, Research. The terms of the Employment Agreement were approved by the Company's Board of Directors.

The Employment Agreement provides for the payment of an annual base salary of \$360,500 with an annual performance bonus target opportunity of up to 35% of his base salary. There are no family relationships between Mr. Bonvini and any director or other officer of the Company or any related party transactions involving Mr. Bonvini.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 10, 2016 MACROGENICS, INC.

/s/Atul Saran

By: Atul Saran

Senior Vice President and General Counsel